MaxCyte, Inc. (MXCT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in th...
Analysis Summary
MaxCyte, Inc. reported revenue of $33.0M in the most recent fiscal year, growing at a 5-year CAGR of 4.8%.
Trailing-twelve-month margins: gross margin 79.4%, operating margin -111.6%, net margin -114.8%.
At the current price of $1.18, MXCT has negative trailing earnings (P/E not meaningful) and an ROE of -21.01%. Market capitalisation stands at $126M.
Balance sheet quality for MXCT: current ratio of 8.3, net cash position of $85.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.18 |
| Market Cap | $126M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.80 |
| EV / EBITDA | -4.29 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -21.01% |
| Return on Invested Capital | -19.66% |
| Return on Assets | -19.30% |
| Gross Margin | 79.43% |
| Operating Margin | -111.63% |
| Net Margin | -114.77% |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 12.26 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 1.43 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MXCT | MaxCyte, Inc. | $126M | 0.80 | -21.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -7.09% |
| 3 months | -2.48% |
| Year-to-date | -23.87% |
| 1 year | -21.33% |
| 3 years | -64.78% |
| 5 years | -91.78% |
52-Week Range
| 52-week High | $1.87 |
| 52-week Low | $0.64 |
| Avg Volume (90d) | 1.1M |
Related companies: ARMP · AVR · CATX · LNSR · NNOX · OWLT · PRE
Explore sector: Healthcare · Biotechnology
More sections of MXCT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks